Vol 14: Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.Reportar como inadecuado



 Vol 14: Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.


Vol 14: Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 14: Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
This article is from BMC Infectious Diseases, volume 14.AbstractBackground: Whether the combination of antimicrobial therapy is a factor in mortality in Pseudomonas aeruginosa bacteremia remains to be elucidated. This study investigated the risk factors for mortality in P. aeruginosa bacteremia patients and the influence of adequate antimicrobial therapy and combination therapy on clinical outcomes. Methods: This retrospective study analyzed data of 234 patients with P. aeruginosa bacteremia at a 1,200-bed tertiary teaching university hospital in South Korea between January 2010 and December 2012. Factors associated with mortality were determined. Mortality was compared in patients with adequate empirical and targeted combination therapy, and monotherapy, and inappropriate therapy. Results: A total of 141 60.3% patients were given appropriate empirical antibiotic treatment combination therapy in 38 and monotherapy in 103. Among 183 patients 78.2% who finally received appropriate targeted treatment, 42 had combination therapy and 141 had monotherapy. The percentage of patients receiving empirical combination therapy was slightly, but not significantly higher, in the survivor group than in the nonsurvivor group 17.0% 31-182 vs. 13.5% 7-52, p = 0.74. A similar tendency was demonstrated for targeted combination therapy 19.8% 36-182 vs. 11.5% 6-52, respectively; p = 0.31. However, in a subgroup analysis of data from patients n = 54 with an absolute neutrophil count less than 500-mm3, the patients who had appropriate empirical or targeted combination therapy showed better outcomes than those who underwent monotherapy or inappropriate therapy p 



Autor: Kim, Youn Jeong; Jun, Yoon Hee; Kim, Yang Ree; Park, Kang Gyun; Park, Yeon Joon; Kang, Ji Young; Kim, Sang Il

Fuente: https://archive.org/







Documentos relacionados